Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 + 14 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new substance called BAY2666605 for adults with advanced cancers that don't respond to current treatments. BAY2666605 helps form a protein complex that makes cancer cells die. The study will see how the drug moves through the body, find the best dose, and check its safety and effectiveness.
Eligible Conditions
- Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 28 + 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 + 14 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence and severity of TEAEs including TESAEs
RP2D of BAY2666605
The incidence of DLTs at each dose level in the Dose Escalation part of the study
Secondary study objectives
DCR
DOR
ORR
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Dose expansion of BAY2666605Experimental Treatment1 Intervention
Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
Group II: Dose escalation of BAY2666605Experimental Treatment1 Intervention
Approximately 7 or 8 dose levels are planned.
Find a Location
Who is running the clinical trial?
BayerLead Sponsor
2,274 Previous Clinical Trials
25,532,376 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger